- Home
- DRUG vs YMAB Comparison
DRUG vs YMAB Comparison
Compare DRUG & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- YMAB
- Stock Information
- Founded
- DRUG 2019
- YMAB 2015
- Country
- DRUG United States
- YMAB United States
- Employees
- DRUG N/A
- YMAB N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DRUG Health Care
- YMAB Health Care
- Exchange
- DRUG Nasdaq
- YMAB Nasdaq
- Market Cap
- DRUG 253.2M
- YMAB 270.5M
- IPO Year
- DRUG N/A
- YMAB 2018
- Fundamental
- Price
- DRUG $36.06
- YMAB $4.73
- Analyst Decision
- DRUG Strong Buy
- YMAB Buy
- Analyst Count
- DRUG 4
- YMAB 11
- Target Price
- DRUG $84.33
- YMAB $19.64
- AVG Volume (30 Days)
- DRUG 50.7K
- YMAB 431.5K
- Earning Date
- DRUG 02-14-2025
- YMAB 03-04-2025
- Dividend Yield
- DRUG N/A
- YMAB N/A
- EPS Growth
- DRUG N/A
- YMAB N/A
- EPS
- DRUG N/A
- YMAB N/A
- Revenue
- DRUG N/A
- YMAB $87,685,000.00
- Revenue This Year
- DRUG N/A
- YMAB $20.07
- Revenue Next Year
- DRUG N/A
- YMAB $8.76
- P/E Ratio
- DRUG N/A
- YMAB N/A
- Revenue Growth
- DRUG N/A
- YMAB 3.38
- 52 Week Low
- DRUG $0.93
- YMAB $4.25
- 52 Week High
- DRUG $79.02
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- DRUG 49.87
- YMAB 32.27
- Support Level
- DRUG $31.55
- YMAB $4.62
- Resistance Level
- DRUG $36.25
- YMAB $5.03
- Average True Range (ATR)
- DRUG 2.74
- YMAB 0.38
- MACD
- DRUG 0.01
- YMAB -0.01
- Stochastic Oscillator
- DRUG 66.15
- YMAB 31.37
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.